

# CURRICULUM VITAE

## William R. Drobyski MD

**Professor**  
**Department of Medicine**  
**Division of Hematology and Oncology - Medicine**

### OFFICE ADDRESS:

Froedtert East Clinics  
9200 W Wisconsin Ave  
Milwaukee, WI 53226

### EDUCATION:

1975 - 1979 B.A., Brown University, Providence, Rhode Island  
1979 - 1983 M.D., University of Rochester School of Medicine and Dentistry, Rochester, New York

### POSTGRADUATE TRAINING AND FELLOWSHIP APPOINTMENTS:

1983 - 1984 Medical Internship, Strong Memorial Hospital, Rochester, NY  
1984 - 1986 Medical Residency, Strong Memorial Hospital, Rochester, NY  
1987 - 1988 Fellowship in Hematology, Strong Memorial Hospital, Rochester, NY  
1988 - 1990 Fellowship in Bone Marrow Transplantation, Medical College of Wisconsin, Milwaukee, WI

### FACULTY APPOINTMENTS:

1986 - 1987 Associate Attending, Emergency Department, Clinical Instructor in Medicine, University of Rochester School of Medicine, Rochester, NY  
1990 - 1994 Assistant Professor of Medicine, Medical College of Wisconsin, Milwaukee, WI  
1991 - Present Full Member, Cancer Center of the Medical College of Wisconsin, Milwaukee, WI  
1994 - 2001 Associate Professor of Medicine, Medical College of Wisconsin, Milwaukee, WI  
1999 - 2001 Associate Professor of Pediatrics (Joint Appointment), Medical College of Wisconsin, Milwaukee, WI  
2001 - Present Professor of Medicine and Pediatrics (With Tenure), Medical College of Wisconsin, Milwaukee, WI  
2005 - Present Professor of Microbiology and Molecular Genetics (Secondary Appointment), Medical College of Wisconsin, Milwaukee, WI  
2010 - Present Program Leader, Transplantation Biology and Immunotherapy Program, Cancer Center, Medical College of Wisconsin, Milwaukee, WI  
2010 - Present Scientific Director, Bone Marrow Transplant Program, Medical College of Wisconsin, Milwaukee, WI

### ADMINISTRATIVE APPOINTMENTS:

1993 - 1998 Medical Consultant - The Blood Center of Southeastern Wisconsin, Molecular Diagnostics and Detection of Minimal Residual Disease, WI

### HOSPITAL AND CLINICAL ADMINISTRATIVE APPOINTMENTS:

1990 - Present Staff Physician, Milwaukee County Medical Complex and Froedtert Memorial, Lutheran Hospital, Milwaukee, WI

### SPECIALTY BOARDS AND CERTIFICATION:

<u>Board Certified</u>	<u>Issue Date</u>	<u>Expiration</u>
Internal Medicine	1986	None

Hematology 1991 None

<u>Licensure</u>	<u>Number</u>	<u>Issue Date</u>	<u>Expiration</u>
Wisconsin	29248		None

**AWARDS AND HONORS:**

1979 - Present Phi Beta Kappa  
1979 - Present Magna Cum Laude  
1980 - Present Victor Meyer Emmel Prize in Medical Histology  
1983 - Present Alpha Omega Alpha  
1983 - Present M.D. with Honors  
1991 - 1996 NIH Clinical Investigator Award  
1995 - Present Listed in Who's Who in Science and Engineering  
1996 - 2001 NIH FIRST Award  
1998 - Present George Santos Prize for the best clinical paper published in Biology of Blood And Marrow Transplantation  
2005 - 2006 Best Doctors in America  
2007 - 2008 Best Doctors in America  
2009 - 2010 Best Doctors in America  
2011 - 2012 Best Doctors in America, 2011-2012  
2011 - Present Excellence in Research Award, Medical College of Wisconsin, Department of Medicine

**MEMBERSHIPS IN HONORARY AND PROFESSIONAL SOCIETIES:**

American Society of Hematology  
American Society for Blood and Marrow Transplantation  
American Association of Immunology

**EDITORSHIPS/EDITORIAL BOARDS/JOURNAL REVIEWS:**

Editorial Board  
2001 - Present Biology of Blood and Marrow Transplantation  
2004 - 2006 Leukemia  
Journal Review  
1995 - Present Bone Marrow Transplantation  
1995 - Present Blood  
1997 - Present Biology of Blood and Marrow Transplantation  
2002 - Present Journal of Immunology  
2003 - Present Experimental Hematology  
2003 - Present Clinical Cancer Research  
2004 - Present Leukemia  
2004 American Journal of Transplantation  
2005 - Present Journal of Clinical Oncology (2005-pres)  
2007 Hematologica  
2007 Leukemia and Lymphoma  
2009 - Present Leukemia Research  
2009 - Present European Journal of Immunology  
American Journal of Hematology  
Transfusion

**NATIONAL ELECTED/APPOINTED LEADERSHIP AND COMMITTEE POSITIONS:**

1995 - 2004 National Institutes of Health-Sponsored Study on T-cell Depletion in Unrelated Marrow Transplantation, Member, Subcommittee on Opportunistic Infections and Immune Reconstitution, Member, Subcommittee on Chimerism  
1996 Abstract Reviewer, "Biology of Engraftment, " American Society of Hematology 38th Annual Meeting, Orlando, FL  
1996 Session Moderator, "Biology of Engraftment, " American Society of Hematology 38th Annual Meeting,

- Orlando, FL
- 1997 Comitato Promotore Telethon ad hoc Grant Reviewer "Pathogenesis and diagnosis of novel human herpes viruses in bone marrow transplant recipients for primary immunodeficiency diseases"
- 1997 Veteran's Administration ad hoc Merit Grant Reviewer
- 1997 - Present Medical Director for the Unrelated Marrow Transplant Program at the Medical College of Wisconsin
- 1997 American Medical Association, Advisory Reviewer, Technology Assessment on "Donor leukocyte infusions for treatment of relapse of chronic myelogenous leukemia after bone marrow transplantation"
- 1998 National Institute of Health, Ad hoc Reviewer, Experimental Therapy 1 Study Section
- 1998 Abstract Reviewer, "Experimental Transplantation-GVHD and Neoplasia", American Society of Hematology, 40th Annual Meeting, Miami Beach, FL
- 1999 Dutch Cancer Society ad hoc Grant Reviewer, "Quantitative monitoring of immune response in patients following immunotherapy with donor lymphocyte infusion"
- 2000 National Institute of Health, Ad hoc Reviewer, Special Emphasis Panel, SCOR in Transfusion Biology and Medicine
- 2000 - 2002 National Institute of Health, Ad hoc Reviewer, Experimental Therapeutics 2 Study Section
- 2001 - Present BMT InfoNet, Scientific Board of Advisors
- 2001 Abstract Reviewer, "Experimental Transplantation-Basic Biology, Regimens and Engraftment", American Society of Hematology, 43rd Annual Meeting, Orlando, FL
- 2002 Session Moderator, "Experimental Transplantation-Basic Biology, Regimens and Engraftment", American Society of Hematology, 44th Annual Meeting, Philadelphia, PA
- 2002 Abstract Coordinating Reviewer, "Experimental Transplantation-Basic Biology, Regimens and Engraftment", American Society of Hematology, 44th Annual Meeting, Philadelphia, PA
- 2002 - 2003 National Institute of Health, Member, Experimental Therapeutics 2 Study Section
- 2003 - 2005 National Institute of Health, Member, Cancer Immunology Immunopathology Study Section, Charter Member
- 2004 Health Research Council of New Zealand, Ad Hoc Grant Reviewer
- 2005 Session Moderator, "Basic Biology, Engraftment and Immune Function", American Society of Hematology, 47th Annual Meeting, Atlanta, GA
- 05/11/2006 Swiss National Science Foundation, Ad Hoc Reviewer, "Allogeneic Hematopoietic Stem Cell Transplantation with Skewed Immune Reconstitution as a Cause of Autoimmunity"
- 2007 Abstract Reviewer, "Basic Biology, Engraftment and Immune Function", American Society of Hematology, 49th Annual Meeting, Atlanta, GA
- 2007 Session Moderator, "Basic Biology, Engraftment and Immune Function", American Society of Hematology, 49th Annual Meeting, Atlanta, GA
- 2008 American Society of Bone Marrow Transplantation Task Force on Research Priorities
- 04/30/2009 Medical Research Council, Ad hoc Grant Reviewer, "Effector and Regulatory CD4+ T cell Imbalance in Clinical Graft versus Host Disease"
- 2009 Session Moderator, Experimental Transplantation - GVHD and GVL: Dissecting GvHD from GvL - The Promise of Lymphocyte Manipulation, American Society of Hematology, 51st Annual Meeting, New Orleans, LA
- 2009 Abstract Reviewer, "Experimental Transplantation-GVHD and GVL", American Society of Hematology, 51st Annual Meeting, New Orleans, LA
- 2010 Abstract Coordinating Reviewer, "Experimental Transplantation-Graft versus Host and Graft versus Leukemia", American Society of Hematology, 52nd Annual Meeting, Orlando, FL

#### **INVITED LECTURES/WORKSHOPS/PRESENTATIONS:**

##### **Local**

- Milwaukee Blood Club, "Treatment Strategies for Resistant CML in the Transplant and Nontransplant Settings", 1993 - Present
- "Donor Leukocyte Infusions: Current Applications and Future Strategies", Hematology/Oncology Grand Rounds, Medical College of Wisconsin, Milwaukee, WI, 1999 - Present
- "Use of Gamma Delta T cells as a Novel Transplantation Strategy to Promote Engraftment without Graft-Versus-Host Disease", Department of Pediatric Academic Conference, Medical College of Wisconsin, Milwaukee, WI, 2000 - Present
- "Regulation of Alloresponses after Allogeneic Stem Cell Transplantation using Thymidine Kinase Gene Modified Donor T Cells", Department of Microbiology and Molecular Genetics Seminar Series,

Medical College of Wisconsin, 08/31/2004 - Present  
"Pivotal Role of Interleukin 23 in Allogeneic Stem Cell Transplantation", Research Conference, Children's Research Institute, Medical College of Wisconsin, Milwaukee, WI, 06/11/2010 - Present

### **Regional**

Donor lymphocyte infusions for relapsed leukemia, Sixth Annual Malnati Symposium in the Clinical Sciences: "Hematopoietic Stem-Cell Transplantation: Advances and Controversies", Northwestern University Medical School, Chicago, IL, 1996 - Present  
"Transplant Outcomes in Unrelated versus Haploidentical Marrow Transplant Recipients", National Marrow Donor Program Annual Meeting, Minneapolis, MN, 2001 - Present

### **National**

ASTRA Pharmaceutical Conference on Herpesvirus Infections in Immunocompromised Patients, "Role of Human Herpesvirus Six Infection in Bone Transplant Recipients, " Westboro, MA, 1991 - Present  
MACC Fund Site Visit, "Preservation of Lymphokine-Activated Killer Activity after Allogeneic Bone Marrow Transplantation, " Milwaukee, WI, 1992 - Present  
UCLA Keystone Symposium on Bone Marrow Transplantation, "Human Herpesvirus Six Infection in Bone Marrow Transplant Recipients, " Keystone, CO, 1994 - Present  
National Institute of Health Workshop on GVHD in Unrelated Bone Marrow Transplantation, "The Role of Donor Leukocyte Infusions in Unrelated Marrow Transplantation, " Bethesda, MD, 1994 - Present  
University of Rochester, City Wide Hematology Conference, "Use of Unrelated Donors in Allogeneic Bone Marrow Transplantation, " Rochester, NY, 1994 - Present  
"Unrelated Donors in Allogeneic Bone Marrow Transplantation, " Washington University, St Louis, MO, 1994 - Present  
Adoptive Immunotherapy Using Donor Leukocyte Infusions as Treatment for Relapsed Disease after Allogeneic BMT, Baylor University, Dallas, TX, 1995 - Present  
Symposium on "Biology and Therapy of Bacterial and Fungal Infections in Leukemia, Lymphoma and Bone Marrow Transplantation", San Diego, CA, 1998 - Present  
"The Case for T Cell Depletion in the Treatment of Chronic Phase Chronic Myelogenous Leukemia After Allogeneic Bone Marrow Transplantation", IBMTR/ABMTR Annual Meeting, Anaheim, CA, 2000 - Present  
"The Regulation of Alloresponses after Bone Marrow Transplantation using Donor T cells Expressing a Thymidine Kinase Suicide Gene", Translational Research Conference, NCI-Frederick, Frederick, MD, 2002 - Present  
"Regulating immune responses after allogeneic bone marrow transplantation using donor T cells expressing a thymidine kinase suicide gene", University of Rochester, Rochester, NY, 2002 - Present  
"How Good is Allogeneic Transplantation for High Risk AML?", Acute Leukemia Forum 2004: "Advances in the Biology and Therapy of Acute Myelogenous Leukemia, San Francisco, CA, 04/16/2004 - Present  
"Convergence of Alloreactivity and Autoreactivity during the Transition from Acute to Chronic Graft versus Host Disease", University of Miami, Miami, FL, 05/30/2007 - Present  
"Targeting NFkB for the Prevention of Graft versus Host Disease", Celgene Inflammation Symposium, San Diego, CA, 06/13/2008 - Present  
"Role on Interleukin 23 in graft versus host disease and graft versus leukemia reactivity after allogeneic stem cell transplantation", Merck/BioSchering Pharma Symposium of the Biology of Interleukin 23, Palo Alto, CA, 02/01/2010 - Present  
"Restrictions on peripheral T cell reconstitution during graft versus host disease", Scientific Session on Immune Reconstitution, How it should work, why it is broken and why it matters", American Society of Blood and Marrow Transplantation, Orlando, Florida, 02/27/2010 - Present  
"Pivotal Role of Interleukin 23 in Allogeneic Stem Cell Transplantation", Bone Marrow Transplant Grand Rounds, Moffitt Cancer Center, Tampa, Florida, 04/12/2011 - Present

### **COMMITTEE SERVICE:**

#### **Medical College of Wisconsin**

1991 - 1999 Fellowship Evaluation Committee, Division of Hematology/Oncology  
1992 - 1998 Bone Marrow Transplant Program Strategic Planning Committee

1992 - 1995 Medical College of Wisconsin Cancer Center Scientific Review Committee  
1994 - 1995 Search Committee, Director, Bone Marrow Transplant Program  
1995 - 1996 Research Task Force, MCW Institutional Strategic Planning Committee  
1996 - Present MCW Cancer Center Grants Review Committee  
2000 - 2002 MCW Medical Student Research Honors Program Committee  
2005 - Present MCW Committee on Immunology  
2006 - Present MCW Immunotherapy of Cancer Committee  
2006 - 2009 MCW In Vivo Core Imaging Committee  
2007 - 2009 Member, Internal Review Board (IRB), Committee #3  
2009 Fellowship Interview Committee, Division of Neoplastic Diseases  
2010 - 2011 Search Committee, Chief of Pediatric Hematology/Oncology  
2010 - Present Executive Committee, Clinical Translation Science Institute, Mentoring Initiative

**Hospital**

1993 - 1997 Transfusion Committee

**MEDICAL COLLEGE TEACHING ACTIVITIES:**

**Medical Student Education**

1990 MCW Bone Marrow Transplant Grand Rounds, "Human Herpesvirus-6 (HHV-6) Infections in BMT Patients"  
1990 - 1992 Director, Bone Marrow Transplant Grand Rounds

**Resident and Fellow Education**

1990 - Present Attend two-four months/year on the Bone Marrow Transplant Service with teaching responsibilities for fellows, residents and mid-level providers.  
2006 - 2011 "Immunobiology of Bone Marrow Transplantation", MCW Hematology/Oncology Fellow Core Education Session, 1 lecture/year

**EXTRAMURAL TEACHING:**

**Community/Lay Public**

10/06/2009 Milwaukee Lutheran High School, Milwaukee, WI, "Role of Radiation in the Therapy of Medical Diseases", Physics Class

**MCW STUDENTS, FACULTY, RESIDENTS AND CLINICAL/RESEARCH FELLOWS MENTORED:**

**Medical Students**

Amar Patel, MCW, 06/1999  
Stephen Miller, MCW, 06/2001  
Jon Anderson, MCW, 06/2006  
Tyce Kearl, MCW, 06/2007  
Anoop Patel, MCW, 06/2008  
Bryce Schuler, MCW, 06/2009  
Scott Kagie, MCW, 2009 - 2010  
Chelsea Tessler-Verville, MCW, 06/2011

**Graduate Students**

**PhD Committees**

Eileen Burd, MCW, 1991 - 1993 "Human Herpesvirus Six - Associated Dysfunction of Cells of the Monocyte/Macrophage Lineage"  
  
Luke Drury, MCW, 2006  
Fallon Noto, MCW, 2006  
Aaron Mull, MCW, 2007  
Fengie Lu, MCW, 2007  
Amy Beres, MCW, 2008 - Present

Lily Du, MCW, 2008  
Lynsi Lowenhagen, MCW, 2009 - 2010  
Alexandra Chadwick, MCW, 2010  
Olena Wiedemayer, MCW, 2010  
Patrick Gonyo, MCW, 2011

#### **Postdoctoral Students**

Elizabeth Tivol, PhD, MCW, 2002 - 2004  
Rupali Das, PhD, MCW, 2006 - 2009  
Will Hallet, PhD, MCW, 2007 - 2011 Co-Mentor with Dr Bryon Johnson  
Hariharan Subramanian, PhD, MCW, 2009

#### **Clinical/Research Fellows**

Parameswaran Hari, MCW, 2003 - 2004  
Nanveer Rand, MCW, 07/2007 - 11/2007  
Hemalatha Rangaran, MCW, 2010 - Present  
Jala Potluri, MCW

#### **Residents**

Frank Cornell, MD, MCW, 06/2009

### **EXTRAMURAL STUDENTS, FACULTY, RESIDENTS, AND CLINICAL/RESEARCH FELLOWS MENTORED:**

#### **Graduate Students**

##### **PhD Committees**

Stephen Jones, Jefferson Medical College, 2003 - 2004 "The Immunobiology of Acute Graft Versus Host Disease across Minor Histocompatibility Antigen Barriers"  
Melinda Rokos Keith, University of Miami, 05/29/2007 "The contribution of homeostatically expanded donor CD8 T cells to host reconstitution following syngeneic hematopoietic cell transplantation"

### **BIBLIOGRAPHY**

#### **Refereed Journal Publications/Original Papers**

1. Qazi R, Chuang J-LC, and **Drobyski WR**. Estrogen receptors and patterns of relapse in breast cancer. Arch Int Med, 144:2365-2370, 1984.
2. **Drobyski WR** and Qazi R. Spontaneous regression in non-Hodgkin's lymphoma: clinical and pathogenetic considerations. Am J Hematol 31:138-141, 1989.
3. **Drobyski WR**, Thibodeau S, Truitt RL, Baxter-Lowe LA, Gorski J, Jenkins R, Gottschall J, and Ash RC. Third party-mediated graft rejection and graft-versus-host disease after T-cell depleted bone marrow transplantation as demonstrated by hypervariable DNA probes and HLA-DR polymorphism. Blood 74:2285-2294, 1989.
4. **Drobyski WR**, Piaskowski V, Ash RC, Casper JT, and Truitt RL. Preservation of lymphokine-activated killer (LAK) activity following T-cell depletion of human bone marrow. Transplantation 50:625-632, 1990.
5. Knox KK, **Drobyski WR**, and Carrigan DR. Cytomegalovirus dually resistant to ganciclovir and foscarnet. Lancet 337:1292-1293, 1991.
6. **Drobyski WR**, Gottlieb M, Carrigan D, Ostberg L, Grebeneau M, Schran H, Magid P, Ehrlich P, Nadler PI, and Ash RC. Phase I study of safety and pharmacokinetics of a human anti-cytomegalovirus monoclonal antibody in allogeneic marrow transplant recipients. Transplantation 51:1190-1196, 1991.
7. **Drobyski WR**, Knox KK, Carrigan DR, and Ash RC. Foscarnet therapy of ganciclovir-resistant cytomegalovirus in marrow transplantation. Transplantation 52:155-157, 1991.
8. Carrigan DR, **Drobyski WR**, Russler SK, Tapper MA, Knox KK, and Ash RC. Interstitial pneumonitis due to human herpes virus-6 (HHV-6) in marrow transplantation. Lancet 338:147-149, 1991.
9. **Drobyski WR**, LeFever AV, and Truitt RL. Regulation of lymphokine-activated killer activity in T-replete and T-cell depleted human bone marrow by interleukin 4. Exp Hematol 19:950-957, 1991.
10. **Drobyski WR**, Roth M, Thibodeau S, and Gottschall J. Molecular remission occurring after donor leukocyte

- infusions for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplant. *Bone Marrow Transplant* 10:301-304, 1992.
11. **Drobyski WR**, Dunne WM, Burd EM, Knox KK, Horowitz MM, Ash RC, Flomenberg N, and Carrigan DR. Human herpesvirus-6 infection in allogeneic bone marrow transplant recipients. I. Evidence of a marrow suppressive role for HHV-6 in vivo. *J Infect Dis* 167:735-739, 1993.
  12. **Drobyski WR**, Baxter-Lowe LA, and Truitt RL. Detection of residual leukemia by the polymerase chain reaction and sequence-specific oligonucleotide probe hybridization after allogeneic bone marrow transplantation for AKR leukemia: A murine model for minimal residual disease. *Blood* 81:551-559, 1993.
  13. **Drobyski WR**, Eberle M, Majewski D, and Baxter-Lowe LA.. Prevalence of human herpesvirus six variant A and B infections in bone marrow transplant recipients as determined by polymerase chain reaction and sequence-specific oligonucleotide probe hybridization. *J Clin Micro* 31:1515-1520, 1993.
  14. **Drobyski WR**, Keever CA, Roth MS, Koethe S, Hanson G, McFadden P, Gottschall JL, Ash RC, Van Tuinen P, Horowitz MM, and Flomenberg N. Salvage immunotherapy using donor leukocyte infusions as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation: Efficacy and toxicity of a defined T-cell dose. *Blood* 82:2310-2318, 1993
  15. Johnson BJ, **Drobyski WR** and Truitt RL. Delayed infusion of normal donor cells after MHC-matched bone marrow transplantation provides an antileukemia reaction without graft-versus-host disease. *Bone Marrow Transplant* 11: 329, 1993.
  16. Flomenberg P, Babbitt J, **Drobyski WR**, Ash RC, Carrigan DR, Sedmark GV, Camitta B, Horowitz MM and Casper JT. Risk of adenovirus disease in bone marrow transplant recipients. *J Infect Dis* 169:775-781, 1994.
  17. **Drobyski WR**, Knox KK, Majewski D and Carrigan DR. Fatal encephalitis due to variant B human herpesvirus six in a bone marrow transplant recipient. *New Engl J Med* 330:1356-1360, 1994.
  18. **Drobyski WR**, Ash RC, Casper JT, McAuliffe T, Horowitz MM, Lawton C, Keever C, Baxter-Lowe LA, Camitta B, Garbrecht F, Pietryga D, Hansen R, Chitambar CR, Anderson T and Flomenberg N. Effect of T-cell depletion as graft-versus-host disease prophylaxis on engraftment, relapse, and disease-free survival in unrelated marrow transplantation for chronic myelogenous leukemia. *Blood* 83:1980-1987, 1994.
  19. Hessner MJ, Roth MS, **Drobyski WR** and Baxter-Lowe LA. Development of a sensitive, highly controlled assay for molecular detection of the Philadelphia chromosome in patients with chronic myelogenous leukemia. *Genet Anal Tech Appl* 11:90-94, 1994.
  20. **Drobyski WR**, Keever CA, Hanson G, McAuliffe T and Griffith OW. Inhibition of nitric oxide production is associated with enhanced weight loss, decreased survival and impaired alloengraftment in mice undergoing graft-versus-host disease after bone marrow transplantation. *Blood* 84:2363-2373, 1994.
  21. Datta YH, Adams PT, **Drobyski WR**, Ethier SP, Terry VH, and Roth MS. Sensitive detection of occult breast cancer by the reverse transcriptase polymerase chain reaction. *J Clin Oncol* 12:475-482, 1994.
  22. Casper J, Camitta B, Truitt R, Baxter-Lowe LA, Bunin N, Lawton C, Murray K, Hunter J, Pietryga D, Garbrecht F, Keever C, **Drobyski W**, Horowitz M, Flomenberg N, Ash R. Unrelated bone marrow transplants for children with leukemia or myelodysplasia. *Blood* 85:2354-2363, 1995.
  23. Baxter-Lowe LA, Keever C, Dinaver D, Davies T, Johnson K, Camitta B, **Drobyski WR**, Garbrecht F, Horowitz M, Pietryga D, Casper J, and Flomenberg N. Use of solid phase automated sequencing to define HLA disparity between bone marrow donors and recipients. *Transplant Proc* 27:1377-1378, 1995.
  24. Sarode R, McFarland JG, Flomenberg N, Casper JT, Cohen E, **Drobyski W**, Ash R, Horowitz M, Camitta B, Lawton C, Garbrecht F, Gottschall J. Therapeutic plasma exchange does not appear to be effective in the management of thrombocytopenic purpura/hemolytic uremic syndrome following bone marrow transplantation. *Bone Marrow Transplant* 16:271-275, 1995.
  25. Hessner MJ, Edean DJ, Casper JT, Horowitz MM, Keever-Taylor CA, Roth M, Flomenberg N, and **Drobyski WR**. Use of unrelated marrow grafts compensates for reduced graft-versus-leukemia reactivity after T-cell depleted allogeneic marrow transplantation for chronic myelogenous leukemia. *Blood* 86:3987-3996, 1995.
  26. **Drobyski WR**, Potluri J, Sauer D, and Gottschall J. Autoimmune hemolytic anemia following T-cell depleted allogeneic bone marrow transplantation. *Bone Marrow Transplant* 17:1093-1099, 1996.
  27. **Drobyski WR** and Majewski D. Treatment of donor mice with an ?? T-cell receptor monoclonal antibody induces prolonged T-cell nonresponsiveness and effectively prevents lethal graft-versus-host disease in murine recipients of MHC-matched and MHC-mismatched marrow grafts. *Blood* 87:5355-5369, 1996.

28. **Drobyski WR**, Ul-Haq R, Majewski D, and Chitambar C. Modulation of in vitro and in vivo T cell responses by transferrin-gallium and gallium nitrate. *Blood* 88:3056-3064, 1996.
29. Collins R, Shpilberg O, **Drobyski W**, Porter D, Giralt S, Champlin R, Wolff S, Hu W, Blume K, Verfaillie C, List A, Ognoskie N, Chetrit A, Antin J and Nemunaitis J. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. *J Clin Oncol* 15:433-444, 1997.
30. **Drobyski WR** and Majewski D. Donor ?? T lymphocytes promote allogeneic engraftment across the major histocompatibility barrier in mice. *Blood* 89:1100-1109, 1997.
31. Kawanishi Y, Passweg J, **Drobyski WR**, Rowlings P, Cook-Craig A, Casper J, Pietryga D, Garbrecht F, Camitta B, Horowitz M, Juckett M, Margolis D, Flomenberg N, and Keever-Taylor CA. Effect of T cell subset dose on outcome following T-cell depleted bone marrow transplantation. *Bone Marrow Transplant* 19:1069-1077, 1997.
32. **Drobyski WR**, Endean DJ, Klein JP, and Hessner MJ. Detection of BCR/ABL RNA transcripts using the polymerase chain reaction is highly predictive for relapse in patients transplanted with unrelated marrow grafts for chronic myelogenous leukemia. *Br J Haematol* 98:458-466, 1997.
33. Lawton CA, Cohen EP, Murray KJ, Derus SW, Casper JT, **Drobyski WR**, Horowitz MM, and Moulder JE. Long term results of selective renal shielding in patients undergoing total body irradiation in preparation for bone marrow transplantation. *Bone Marrow Transplant* 20:1069-1074, 1997.
34. Juckett M, Rowlings P, Hessner M, Keever-Taylor C, Burns W, Camitta B, Casper J, **Drobyski WR**, Hanson G, Horowitz M, Lawton C, Margolis D, Pietryga D, and Vesole D. T-Cell depleted allogeneic bone marrow transplantation for high risk non-hodgkin lymphoma: Clinical and molecular follow-up. *Bone Marrow Transplant* 21: 893-899, 1998.
35. Link CJ, Burt RK, Traynor AE, and **Drobyski WR**. Adoptive Immunotherapy for Leukemia: Donor Lymphocytes Transduced with the Herpes Thymidine Kinase Gene for Remission Induction. *Human Gene Ther* 9:115-134, 1998.
36. **Drobyski WR**, Pelz C, Kabler-Babbitt C, Hessner M, Baxter-Lowe LA, and Keever-Taylor CA. Successful unrelated marrow transplantation for patients with chronic myelogenous leukemia over the age of forty. *Biol Blood Marrow Transplant* 4: 3-12, 1998.
37. **Drobyski WR** and Hessner M. The use of the polymerase chain reaction to predict for subsequent relapse in unrelated marrow transplantation for chronic myelogenous leukemia. *Leuk Lymphoma* 31: 317-323, 1998.
38. **Drobyski WR**, Majewski D, Ozker K, and Hanson G. Ex vivo anti-CD3 antibody activated donor T cells have a reduced ability to cause lethal murine graft-versus-host disease but retain their ability to facilitate alloengraftment. *J Immunol* 161: 2610-2619, 1998.
39. Porter DL, Collins RH, Shpilberg O, **Drobyski WR**, Sproules A and Antin JH. Long term follow up of 66 patients who achieved complete remission after donor leukocyte infusions for relapse after allogeneic bone marrow transplantation. *Biol Blood Marrow Transplant* 5:253-261, 1999.
40. **Drobyski WR**, Hessner MJ, Klein JP, Kabler-Babbitt C, Vesole DH and Keever-Taylor CA. T cell depletion plus salvage immunotherapy with donor leukocyte infusions as a strategy to treat chronic phase chronic myelogenous leukemia patients undergoing HLA-identical sibling marrow transplantation. *Blood* 94: 434-441, 1999.
41. **Drobyski WR**, Majewski D and Hanson G. Graft facilitating doses of ex vivo activated gamma delta T cells do not cause lethal murine graft-versus-host disease. *Biol Blood Marrow Transplant* 5: 222-230, 1999.
42. Burt RK, **Drobyski WR** and Link CJ. Herpes simplex thymidine kinase transgenic donor lymphocytes. *Bone Marrow Transplant* 24: 1043-1051, 1999.
43. Porter DL, Collins RH, Hardy C, Kernan NA, **Drobyski W**, Giralt S, Flowers MED, Casper J, Leahey A, Parker P, Mick R, Bate-Boyle B, King R and Antin JH. Treatment of relapsed leukemia after unrelated donor marrow transplantation with unrelated donor leukocyte infusions. *Blood* 95: 1214-1221, 2000.
44. Champlin RE, Passweg JR, Zhang M, Rowlings PA, Pelz C, Atkinson KA, Barrett AJ, Cahn J-Y, **Drobyski WR**, Gale RP, Goldman JM, Gratwohl A, Gordon-Smith EC, Henslee-Downey PJ, Herzig RH, Klein JP, Marmont AM, O'Reilly RJ, Ringden O, Slavin S, Sobocinski KA, Speck B, Weiner RS, Horowitz MM. T cell depletion of bone marrow transplants for leukemia from donors other than HLA-identical siblings: Advantage of T cell antibodies with narrow specificities. *Blood* 95: 3996-4003, 2000.
45. Luhm RA, Bellissimo DB, Uzgiris AJ, **Drobyski WR** and Hessner MJ. Quantitative evaluation of post bone marrow transplant engraftment status using fluorescently-labeled variable number of tandem repeats (VNTRs). *Molecular Diagnosis* 5:129-138, 2000.
46. **Drobyski WR**, Vodanovic-Jankovic S and Klein J. Adoptively transferred ?? T cells indirectly regulate



- murine graft versus host reactivity following donor leukocyte infusion therapy in mice. *J Immunol* 165:1634-1640, 2000.
47. **Drobyski WR**. Evolving strategies to address adverse transplant outcomes associated with T cell depletion. *J Hematother Stem Cell Research* 9: 327-337, 2000.
  48. Collins RH, Goldstein S, Giralt S, Levine J, Porter D, **Drobyski W**, Barrett J, Johnson M, Kirk A, Horowitz M and Parker P. Donor leukocyte infusions in acute lymphocytic leukemia. *Bone Marrow Transplant* 5: 511-516, 2000.
  49. Salama M, Nevill T, Marcellus D, Parker P, Johnson M, Kirk A, Porter D, Giralt S, Levine JE, **Drobyski W**, Barrett J, Horowitz M and Collins R. Donor leukocyte infusions for multiple myeloma. *Bone Marrow Transplant* 26: 1179-1184, 2000.
  50. **Drobyski WR**, Morse HC, Burns WH, Casper JT and Sandford G. Protection from lethal graft versus host disease without compromise of alloengraftment using transgenic donor T cells expressing a thymidine kinase suicide gene. *Blood* 97: 2506-2513, 2001.
  51. Keever-Taylor CA, Bredeson C, Vesole DH and **Drobyski WR**. Analysis of risk factors for the development of GVHD after T cell depleted allogeneic BMT: Effect of HLA disparity, ABO incompatibility and method of T cell depletion. *Biol Blood Marrow Transplant* 7: 620-630, 2001.
  52. Levine JE, Braun T, Penza SL, Beatyy P, Cornetta K, Martino R, **Drobyski WR**, Barrett AJ, Porter DL, Giralt S, Leis J, Johnson M, Horowitz M and Collins RH. A prospective trial of chemotherapy and donor leukocyte infusions for relapse of advanced myeloid malignancies following allogeneic stem cell transplantation. *J Clin Oncol* 20: 405-412, 2002.
  53. **Drobyski WR**, Klein J, Flomenberg N, Pietryga D, Vesole DH, Margolis DA and Keever-Taylor CA. Superior survival associated with transplantation of matched unrelated versus one antigen mismatched unrelated or highly HLA-disparate haploidentical family donor marrow grafts for the treatment of hematologic malignancies: Establishing a treatment algorithm for recipients of alternative donor grafts. *Blood* 99: 806-814, 2002.
  54. **Drobyski WR**, Komorowski R, Logan B and Gendelman M. Role of the passive apoptotic pathway in graft versus host disease. *J Immunol* 169: 1626-1633, 2002.
  55. **Drobyski WR** and Gendelman M. Regulation of alloresponses after bone marrow transplantation using donor T cells expressing a thymidine kinase suicide gene. *Leuk Lymph* 43: 2011-2016, 2002.
  56. Rosenblum M, **Drobyski WR**, Keever-Taylor CA and Chang C. Concurrent presence of both patient and donor t(14;18) in a follicular lymphoma patient after undergoing allogeneic BMT-Implications for minimal residual disease detection post-transplant. *Bone Marrow Transplant* 31: 947-949, 2003.
  57. **Drobyski WR**, Gendelman M, Vodanovic-Jankovic and Gorski J. Elimination of leukemia in the absence of lethal graft versus host disease. *J Immunol* 170: 3046-3053, 2003.
  58. Burt RK\*, **Drobyski W\***, Seregina T, Traynor A, Oyama Y, Keever-Taylor C, Stefka J, Kuzel T, Burns W and Link C. Herpes simplex thymidine kinase gene transduced donor lymphocyte infusions for relapsed hematologic malignancies following allogeneic hematopoietic stem cell transplantation. *Exp Hematol* 31: 903-910, 2003. (\* Both authors contributed equally to this work).
  59. Gendelman M, Yassai M, Tivol E, Krueger A, Gorski J and **Drobyski WR**. Selective elimination of alloreactive donor T cells attenuates graft versus host disease and enhances T cell reconstitution. *Biol Blood Marrow Transplant* 9: 742-752, 2003.
  60. Gendelman M, Hecht T, Logan B, Vodanovic-Jankovic S, Komorowski R and **Drobyski WR**. Host conditioning is a primary determinant in modulating the effect of interleukin 7 on murine graft versus host disease. *J Immunol* 172: 3328-3336, 2004.
  61. **Drobyski WR**. The Role of Allogeneic Transplantation in High-Risk Acute Myelogenous Leukemia. *Leukemia* 18: 1565-1568, 2004 (Keynote Address).
  62. Hari P, Logan B and **Drobyski WR**. Temporal discordance between graft versus leukemia and graft versus host responses: A strategy for the separation of GVL/GVH reactivity? *Biology Blood Marrow Transplantation* 10: 743-747, 2004.
  63. Gendelman M, Halligan N, Komorowski R, Logan B, Murphy WJ, Blazar BR, Pritchard K and **Drobyski WR**. Phenyl-tert-butyl-nitrone protects syngeneic marrow transplant recipients from the lethal cytokine syndrome occurring after agonistic CD40 antibody administration. *Blood* 105: 428-431, 2005.
  64. Tivol E, Komorowski R and **Drobyski WR**. Emergent autoimmunity in graft versus host disease. *Blood* 105: 4887-4893, 2005.
  65. Hari P and **Drobyski WR**. Bortezomib in the management of relapsed multiple myeloma. In *Scope*

- Oncology and Hematology 2: 3-6, 2005.
66. Vodanovic-Jankovic S, Hari P, Jacobs P, Komorowski R and **Drobyski WR**. NF- $\kappa$ B as a target for the prevention of graft versus host disease: Comparative efficacy of bortezomib and PS-1145. *Blood* 107:827-834, 2006.
  67. Vodanovic-Jankovic S and **Drobyski WR**. Gamma delta T cells do not require fully functional cytotoxic pathways or the ability to recognize recipient alloantigens to prevent graft rejection. *Biol Blood Marrow Transplant* 12: 1125-1134, 2006.
  68. Cohen EP, **Drobyski WR** and Moulder JE. Sixteen-fold increase in end stage renal disease after hematopoietic stem cell transplantation. *Bone Marrow Transplant* 39: 571-572, 2007.
  69. Gorski J, Chen X, Gendelman M, Yassai M, Krueger A, Tivol E, Logan B, Komorowski R, Vodanovic-Jankovic S, and **Drobyski WR**. Homeostatic expansion and repertoire regeneration of donor T cells during graft versus host disease is constrained by the host environment. *Blood* 109: 5502-5510, 2007.
  70. Chen X, Vodanovic-Jankovic S, Johnson B, Keller M, Komorowski R, **Drobyski WR**. Absence of regulatory T cell control of TH1 and TH17 cells is responsible for the autoimmune-mediated pathology in chronic graft versus host disease. *Blood* 110: 3804-3813, 2007. Recognized by Faculty 1000 Biology as a recommended paper of interest August 24, 2007; <http://www.f1000biology.com/article/id/1089415>
  71. Cohen EP, Irving AA, **Drobyski WR**, Klein JP, Passweg J, Talano JM, Juckett MB, and Moulder JE. Captopril to mitigate chronic renal failure after hematopoietic stem cell transplantation: a randomized controlled trial. *Int J Rad Oncol Biol Phys* 70: 1546-1551, 2008.
  72. Levine JE, Barrett AJ, Zhang MJ, Arora M, Pulsipher MA, Bunin N, Fort J, Loberiza F, Porter D, Giralt S, **Drobyski W**, Wang D, Pavletic S, Ringden O, Horowitz M, Collins R. Donor leukocyte infusions to treat hematologic malignancy relapse after allogeneic stem cell transplantation in a pediatric population. *Bone Marrow Transplant* 42:201-205, 2008.
  73. **Drobyski WR**, Hari P, Keever-Taylor CA, Komorowski R, Grossman W. Severe autologous graft versus host disease after hematopoietic progenitor cell transplantation for multiple myeloma. *Bone Marrow Transplant* 43: 169-177, 2009.
  74. Das R, Chen X, Komorowski R, Hessner MJ, **Drobyski WR**. Interleukin 23 secretion by donor antigen presenting cells is critical for organ-specific pathology in graft versus host disease. *Blood* 113: 2352-2362, 2009.
  75. Chen X, Das R, Komorowski R, Beres A, Hessner MJ, Mihara M, **Drobyski WR**. Blockade of interleukin 6 signaling augments regulatory T cell reconstitution and attenuates the severity of graft versus host disease. *Blood* 2009; 114: 891-900. Recognized by Faculty 1000 Biology as a recommended paper of interest June 9, 2009; <http://www.f1000biology.com/article/id/1161030>
  76. Filicko-O'Hara J, Filicko J, Grosso D, Flomenberg PR, Friedman TM, Brunner J, **Drobyski W**, Ferber A, Kahkniashvili I, Keever-Taylor C, Moorkerjee B, Talano J,A, Wagner JL, Korngold R, Flomenberg N. Anti-viral responses following LLME-treated lymphocyte infusions: Graft versus infection without graft versus host disease. *Biol Blood Marrow Transplant* 15: 1609-1619, 2009.
  77. Chen X, Das R, Komorowski R, van Snick J, Uyttenhove C, **Drobyski WR**. Interleukin 17 is not required for autoimmune-mediated pathological damage during chronic graft versus host disease. *Biol Blood Marrow Transplant* 16: 123-128, 2010.
  78. Johnson B, **Drobyski W**, Blazar B, Korngold R. Robert Truitt Tribute. *Biol Blood Marrow Transplant* 16: 143-144, 2010.
  79. Sukumaran S, George B, Nair H, **Drobyski WR**. Posterior reversible encephalopathy syndrome in association with high dose steroids after autologous peripheral blood stem cell transplantation. *Bone Marrow Transplant* 45:779-80, 2010.
  80. Gress RE, Emerson SG, **Drobyski WR**. Immune reconstitution: How it should work, what's broken, and why it matters. *Biol Blood Marrow Transplant* 16: S133-S137, 2010.
  81. Das R, Komorowski R, Hessner MJ, Subramanian H, Huettner CS, Cua D, **Drobyski WR**. Blockade of interleukin 23 signaling results in targeted protection of the colon and allows for separation of graft versus host and graft versus leukemia responses. *Blood* 115: 5249-5258, 2010.
  82. Cogbill CH, **Drobyski WR**, Komorowski RA. Gastrointestinal pathology of autologous graft versus host disease following hematopoietic stem cell transplantation: a clinicopathologic study of 17 cases. *Mod Pathol* 24: 117-125, 2011.
  83. Hallett WHD, Jing W, **Drobyski WR**, Johnson BD. Immunosuppressive effects of multiple myeloma are overcome by PD-L1 blockade. *Biol Blood Marrow Transplant* 2011 (in press).
  84. Beres A, Komorowski R, Mihara M, **Drobyski WR**. Instability of Foxp3 expression limits the ability of

induced regulatory T cells to mitigate graft versus host disease. *Clin Cancer Res* 2011 (in press).

### **Books, Chapters, and Reviews**

1. Truitt RL, Horowitz MM, Atasoylu AA, **Drobyski WR**, Johnson BD, and LeFever AV. Graft-versus-leukemia effect of allogeneic bone marrow transplantation: Clinical and experimental aspects of late leukemia relapse. In: *Cellular and Immune Mechanisms and Tumor Dormancy*, T.H. Stewart, E.F. Wheelock, Eds. CRC Press, 1992, pp 111-128.
2. Cook-Craig A, Owen A, Reeder G, **Drobyski WR**, Horowitz M, Brunner J, Flomenberg N, and Keever C. Component processing and intraoperative autotransfusion during bone marrow harvest. Fourth International Symposium on Advances in Bone Marrow Purging and Processing. *Prog Clin Biol Res* 389:613-619, 1994.
3. **Drobyski WR**. Adoptive immunotherapy using donor leukocyte infusions to treat relapsed hematologic malignancies after allogeneic bone marrow transplantation in Allogeneic Hematopoietic Stem Cell Transplantation (ed. R Burt), Kluwer Academic Publishers, pp.233-266, 1999.

### **Abstracts**

1. **Drobyski WR**, Thibodeau S, Jenkins R, Gottschall J, Truitt RL, and Ash RC: Novel "third party" mediated graft rejection (and graft-versus-host disease) following T-cell depleted bone marrow transplantation as demonstrated by a hypervariable "mini-satellite" DNA probe. 33rd Annual Meeting of the American Society of Hematology, San Antonio, Texas, December 1988 (Poster Presentation).
2. **Drobyski WR**, LeFever A, and Truitt RL: Kinetic analysis of lymphokine regulation of bone marrow-derived LAK cells. Society of Biologic Therapy, Williamsburg, Virginia, November, 1989, (Poster Presentation).
3. **Drobyski WR**, Piaskowski V, Ash RC, and Truitt RL: Preservation of lymphokine-activated killer (LAK) activity following T-cell depletion of human bone marrow. UCLA Bone Marrow Transplantation Symposia, Keystone, Colorado, January 1990 (Poster Presentation).
4. **Drobyski WR**, Gottlieb M, Carrigan DR, Ostberg L, Grebeneau M, Schran H, Magid P, Ehrlich P, Nadler PI, and Ash RC: Phase I study of safety and pharmacokinetics of a human anti-cytomegalovirus monoclonal antibody in allogeneic marrow transplant recipients. International Society for Experimental Hematology, Seattle, Washington, August 1990. (Poster Presentation).
5. Carrigan DR, Russler SK, **Drobyski WR**, Knox KK, and Tapper MA: Human herpesvirus-6 (HHV-6)-associated interstitial pneumonitis in two bone marrow transplant patients. Fifteenth International Herpesvirus Workshop, Washington, D.C., August 1990.
6. Truitt RL, Casper JT, **Drobyski WR**, and Ash RC: Clinical and laboratory investigations in T-cell depleted allogeneic bone marrow transplantation. Proc. 28th Annual Meeting, Association for Gnotobiotics, Buffalo, New York, October 1990.
7. **Drobyski WR**, McOlash L, Ash RC, and Truitt RL: Comparative analysis of T-cell depletion techniques: Implications for the antileukemic efficacy of T-cell depleted allogeneic bone marrow transplantation. 34th Annual Meeting of the American Society of Hematology, Denver, Colorado, December 1991. (Poster Presentation).
8. **Drobyski WR**, Dunne WM, Burd E, Knox KK, and Carrigan DR: Human Herpesvirus 6 Infection in Allogeneic Bone Marrow Transplant Recipients. UCLA Bone Marrow Transplant Symposia, Keystone, Colorado, January 1992. (Oral Presentation).
9. **Drobyski WR**, Dunne WM, Burd E, Knox KK, Ash RC, Horowitz MM, Flomenberg N, and Carrigan DR: Human Herpesvirus (HHV-6) infection in bone marrow transplant recipients. I. Evidence of a marrow suppressive role for HHV-6 in vivo. Seventeenth International Herpesvirus Workshop, Edinburgh, Scotland, July 1992.
10. Drobyski, WR, Keever C, Roth M, Koethe S, Hanson G, McFadden P, Gottschall J, Horowitz M, Ash R, and Flomenberg N: Donor leukocyte infusions as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation. 35th Annual Meeting of the American Society of Hematology, Anaheim, CA, Blood 80:66a, 1992. (Poster Presentation).
11. Baxter-Lowe, LA, Casper J, Flomenberg N, Dinauer D, Camitta B, **Drobyski WR**, Garbrecht F, Pietryga D, Horowitz M, Anderson T, Chitambar C, Hansen R, Lawton C, Bunin N, Keever C, Pierce K, and Ash RC: Impact of HLA disparity in bone marrow transplantation. Annual Meeting of the American Association of Immunology. *J Immunol* 150:321a, 1993.
12. Cook-Craig A, Owen A, Reeder G, **Drobyski WR**, Horowitz M, Brunner J, Flomenberg N, and Keever C: Component processing and intraoperative autotransfusion during bone marrow harvest. International

- Society of Hematotherapy and Graft Engineering, Orlando, FL, September 1993.
13. Kawanishi Y, Flomenberg N, Craig A, **Drobyski WR**, Horowitz M, Casper J, Camitta B, Pietryga D, Garbrecht F and Keever C: Effect of T-cell subset content on acute graft-versus-host disease following T-cell depleted bone marrow transplantation. 36th Annual Meeting of the American Society of Hematology, St. Louis, MO, Blood 82:423a, 1993. (Poster Presentation).
  14. Hessner MJ, Roth MS, **Drobyski WR** and Baxter-Lowe LA: Development and implementation of a sensitive highly controlled assay system for molecular detection of the Philadelphia chromosome in patients with chronic myelogenous leukemia. 36th Annual Meeting of the American Society of Hematology, St. Louis, MO, December 1993. (Poster Presentation).
  15. **Drobyski WR**, Ash RC, Casper JT, McAuliffe T, Horowitz MM, Lawton C, Keever C, Baxter-Lowe LA, Camitta B, Garbrecht F, Pietryga D, Hansen R, Chitambar CR, Anderson T and Flomenberg N: Effect of T-cell depletion as graft-versus-host disease prophylaxis on engraftment, relapse, and disease-free survival in unrelated marrow transplantation for chronic myelogenous leukemia. 36th Annual Meeting of the American Society of Hematology, St. Louis, MO, Blood 82:423a, 1993. (Poster Presentation).
  16. Sarode R, McFarland JG, Flomenberg N, Casper JT, Cohen E, **Drobyski WR**, Horowitz M, Camitta B, Garbrecht F, Pietryga D, Lawton C, Ash R, and Gottschall J: Therapeutic plasma exchange is not effective in the management of TTP/HUS following bone marrow transplantation. 36th Annual Meeting of the American Society of Hematology, St. Louis, MO, December 1993. (Poster Presentation).
  17. Baxter-Lowe LA, Keever C, Daniels T, Dinauer D, Johnson K, Casper J, **Drobyski W**, Pietryga D, Garbrecht F, Horowitz M and Flomenberg N: Use of solid phase automated sequencing to define HLA disparity between bone marrow donors and recipients, Fifteenth Congress of the Transplantation Society. *Transplant Proc* 27:1377-1378, 1994.
  18. **Drobyski WR**, Majewski D, Loebel A, Garbrecht F: Abrogation of lethal graft-versus-host disease (GVHD) in mice by administration of ?? T-cell receptor modulated T cells. 37th Annual Meeting of the American Society of Hematology, Nashville, TN, Blood 84 (Suppl 1): 97a, 1994. (Poster Presentation).
  19. Potluri J, Gottschall J, Sauer D, **Drobyski WR**: Autoimmune hemolytic anemia (AIHA) following T-cell depleted (TCD) allogeneic bone marrow transplantation (BMT). 37th Annual Meeting of the American Society of Hematology, Nashville, TN, Blood 84 (Suppl 1): 493a, 1994. (Poster Presentation).
  20. Keever KA, Kawanishi Y, Wank T, Chaltry M, Craig A, **Drobyski WR**, Horowitz M, Casper J, Camitta B, Pietryga D, Garbrecht F, Flomenberg N, Baxter-Lowe LA: Correlation of T cell dose and CTL precursor frequency with graft versus host disease and survival after unrelated or partially matched related BMT. American Society of Hematology, Nashville, TN, Blood 84 (Suppl 1): 99a, 1994.
  21. Pietryga D, Casper J, Garbrecht F, Camitta B, **Drobyski W**, Horowitz M, Lawton C, Keever C, Baxter-Lowe L, Murray K, Pierce K, Cadwallader S, McAuliffe T, and Flomenberg N. Haploidentical bone marrow transplantation (BMT) for hematologic malignancies. *Blood* 84 (Suppl 1): 339a, 1994. (Poster Presentation).
  22. Hessner M, Endean D, Casper J, Horowitz M, Taylor C, Roth M, Flomenberg N, and **Drobyski W**. Use of unrelated marrow grafts compensates for reduced graft-versus-leukemia reactivity after T-cell depleted allogeneic BMT for chronic myelogenous leukemia. 37th Annual Meeting of the American Society of Hematology, Seattle, WA, Blood 86 (Suppl 1): 289a, 1995. (Oral Presentation).
  23. **Drobyski WR**, and Majewski D. ?? T cells prevent allogeneic marrow graft rejection in mice without causing graft-versus-host disease. 37th Annual Meeting of the American Society of Hematology, Seattle, WA, Blood 86 (Suppl 1): 572a, 1995.
  24. Juckett M, Rowlings P, **Drobyski W**, Horowitz M, Lawton C, Keever C, Pietryga D, Casper J, Camitta B, Margolis D, Hanson G. T-cell depleted allogeneic bone marrow transplant for non-Hodgkin's lymphoma: A single institution experience in 32 patients. 37th Annual Meeting of the American Society of Hematology, Seattle, WA, Blood 86 (Suppl 1): 210a, 1995. (Poster Presentation).
  25. Collins R, Shpilberg O, **Drobyski W**, Porter D, Antin J, Wolff S, Giralt S, Chetrit A, Ognoskie N, Prine S, Nemunaitis J. Donor leukocyte infusion (DLI) for post-bone marrow transplant (BMT) relapse - Retrospective cohort analysis of 141 cases. 37th Annual Meeting of the American Society of Hematology, Seattle, WA, Blood 86 (Suppl 1): 563a, 1995.
  26. Kawanishi Y, Wank T, Chaltry M, Craig A, **Drobyski W**, Horowitz M, Casper J, Camitta B, Pietryga D, Garbrecht F, Flomenberg N, Taylor C. Association of infused T-cell subset dose with acute graft-versus-host disease following transplantation of T-cell depleted bone marrow. *Proc American Society for Blood and Marrow Transplantation*, Keystone, CO, 1995.

27. Kawanishi Y, Passweg J, **Drobyski WR**, Cook-Craig A, Casper J, Pietryga D, Garbrecht F, Camitta B, Horowitz M, Juckett M, Margolis D, Rowlings P, Flomenberg N, Keever-Taylor CA. Effect of T-cell subset dose on outcome of T-cell depleted bone marrow transplantation. *Biol Blood Marrow Transplant* 2:150, 1996.
28. **Drobyski WR**. Donor lymphocyte infusions for relapsed leukemia. Proceedings of the Sixth Annual Malnati Symposium in the Clinical Sciences: Hematopoietic Stem-cell Transplantation Advances and Controversies, Northwestern University Medical School, Chicago, IL, July 1996.
29. **Drobyski WR**, Ul-Haq R, Majewski D, Chitambar CR. Gallium nitrate inhibits T cell activation and experimental graft versus host disease in mice. 38th Annual Meeting of the American Society of Hematology, Orlando, FL, Blood 88 (Suppl 1): 229b, 1996. (Poster Presentation).
30. Pietryga D, Casper J, Margolis D, Camitta B, Garbrecht F, **Drobyski W**, Horowitz M, Burns W, Juckett M, Rowlings P, Passweg J, Lawton C, Taylor C, Baxter-Lowe L, Murray K, Pierce K, McAuliffe T, Flomenberg N. Bone marrow transplantation (BMT) using genotypically haploidentical donors. 38th Annual Meeting of the American Society of Hematology, Orlando, FL, Blood 88 (Suppl 1): 264a, 1996.
31. **Drobyski WR**, Horowitz M, Pietryga D, Margolis D, Juckett M, Burns W, Camitta B, Rowlings P, Keever-Taylor C, and Casper J. Unrelated donor marrow transplantation for acute myelogenous leukemia (AML), myelodysplasia, and secondary AML. 38th Annual Meeting of the American Society of Hematology, Orlando, FL, Blood 88 (Suppl 1): 269a, 1996. (Poster Presentation).
32. **Drobyski WR**, Pelz C, Kabler-Babbitt K, Hessner M, and Keever-Taylor C. Successful unrelated marrow transplantation for patients with chronic myelogenous leukemia (CML) over the age of 40. 39th Annual Meeting of the American Society of Hematology, San Diego, CA, Blood 90 (Suppl 1): 107a, 1997. (Poster Presentation).
33. Baxter-Lowe LA, Parrish R, Margolis D, Szmania S, Serynck K, White J, Wank T, Molter M, Hazlett L, **Drobyski W**, Garbrecht F, Pietryga D, Horowitz M, Camitta B, Vesole D, Burns W, Flomenberg N, Casper J,
34. and Keever-Taylor C. HLA disparity detected by automated nucleotide sequencing may aid in selection of alternative donors. 39th Annual Meeting of the American Society of Hematology, San Diego, CA, Blood 90 (Suppl 1): 109a, 1997.
35. Drobyski, WR, Majewski D, Ozker K, and Hanson G. Ex vivo anti-CD3 antibody activated donor T cells have a reduced ability to cause lethal murine graft-versus-host disease (GVHD) but retain their ability to facilitate alloengraftment. 30th Annual Meeting of the American Society of Hematology, San Diego, CA, Blood 90 (Suppl 1): 396a, 1997. (Oral Presentation).
36. Porter DL, Collins R, **Drobyski W**, Connors JM, Van Hoef M, and Antin J. Long term follow-up of 55 patients who achieved complete remission (CR) after donor leukocyte infusions (DL) for relapse after allogeneic bone marrow transplantation. 39th Annual Meeting of the American Society of Hematology, San Diego, CA, Blood 90 (Suppl 1): 549a, 1997.
37. Porter D, Collins R, Mick R, Kernan N, Giralt S, Flowers M, Casper J, **Drobyski W**, Leahey A, Parker P, Bates B, King R, and Antin J. Unrelated donor leukocyte infusions (U-DLI) to treat relapse or EBC-lymphoproliferative disease (EBV-LPD) after unrelated donor bone marrow transplantation (BMT). 39th Annual Meeting of the American Society of Hematology, San Diego, CA, Blood 90 (Suppl 1): 590a, 1997.
38. Margolis D, Gorski J, Truitt R, Taylor C, and **Drobyski W**. Alterations in T cell repertoire during donor leukocyte infusions (DLI). 1st International Symposium on Minor Histocompatibility Antigens, Bar Harbor, Maine, 1997.
39. Stefka J, Hoeft J, Traynor A, Furtado M, Rosen S, Taylor C, Burns W, **Drobyski W**, Link C, Seregina T, and Burt Transduction of donor lymphocytes with the herpes simplex thymidine kinase (HStk) gene. 1998 IBMTR/ABMTR Participants' Meeting, Keystone, CO, January 1998.
40. Dinauer DM, **Drobyski WR**, Margolis DA, Casper JT, Keever-Taylor CA and Hessner MJ. Multi-resolution nested primer PCR assay for rapid detection and identification of fungi in human blood. 40th Annual Meeting of the American Society of Hematology, Miami, FL, Blood 92 (Suppl 1): 283a, 1998.
41. Wagner JE, King R, Kollman C, Anasetti C, Antin JH, Casper J, Champlin R, Davies SM, **Drobyski W**, Fay J, Filipovich A, Heslop H, Karanes C, Kernan N, Nademanee A, Schmeckpeper B and Howe C. Unrelated donor bone marrow transplantation in 5075 patients with malignant and non-malignant disorders: Impact of marrow T cell depletion. 40th Annual Meeting of the American Society of Hematology, Miami, FL, Blood 92 (Suppl 1): 686a, 1998.
42. **Drobyski WR**, Majewski D, and Hanson G. Graft facilitating doses of ex vivo activated ?? T cells do not

- cause lethal murine graft-versus- host disease and thereby have a superior therapeutic index when compared to limiting numbers of naïve ?? T cells. 40th Annual Meeting of the American Society of Hematology, Miami, FL, Blood 92 (Suppl 1): 720a, 1998. (Oral Presentation).
43. **Drobyski WR**, Klein J, Pietryga D, Flomenberg N, Kabler-Babbitt, Vesole DH, Margolis DA, Keever-Taylor CA, Horowitz M, Juckett M, Rizzo JD, Bauer D, Burns WH and Casper JT. A comparative analysis of transplant outcomes in patients receiving unrelated versus highly HLA-disparate haploidentical family member donor marrow grafts for the treatment of leukemia. 41th Annual Meeting of the American Society of Hematology, New Orleans, LA, Blood 94: 564a, 1999. (Oral Presentation).
  44. **Drobyski WR**, Agostini T, Burns WH, Morse H and Sandford G. Mitigation of murine graft versus host disease without compromise of alloengraftment using transgenic donor T cells expressing a thymidine kinase suicide gene. 41th Annual Meeting of the American Society of Hematology, New Orleans, LA, Blood 94: 550a, 1999. (Poster Presentation).
  45. Link CJ, **Drobyski WR**, Traynor AE, Seregina T, Taylor CA, Burns WH, Rosen ST, Burt RK. Adoptive immunotherapy for leukemia: Donor lymphocytes transduced with the herpes simplex thymidine kinase gene. 41th Annual Meeting of the American Society of Hematology, New Orleans, LA, Blood 94: 366a, 1999.
  46. Levine JE, Penza S, Topolsky D, Beatyy P, Rifkin R, Giralt S, Porter DL, **Drobyski WR**, Horowitz MM, Collins RH. Prospective trial of chemotherapy plus donor leukocyte infusions to treat relapsed advanced myeloid leukemia after related bone marrow transplantation. 41th Annual Meeting of the American Society of Hematology, New Orleans, LA, Blood 94: 668a, 1999.
  47. **Drobyski WR**, Morse HC, Burns WH and Sandford G. Modulation of alloengraftment, graft versus host, and graft versus leukemia reactivity using transgenic donor T cells expressing a thymidine kinase suicide gene: Effect of T cell dose and ganciclovir schedule. 42nd Annual Meeting of the American Society of Hematology, San Francisco, CA, Blood
  48. **Drobyski WR**, Klein J, Pietryga D, Flomenberg N, Kabler-Babbitt C, Vesole D, Margolis D, Keever-Taylor C, Bauer D, Burns W and Casper J. Superior survival associated with transplantation of matched unrelated versus highly HLA-disparate haploidentical family marrow grafts for the treatment of leukemia: Establishing a treatment algorithm for recipients of alternative donor grafts. 42nd Annual Meeting of the American Society of Hematology, San Francisco, CA, (Oral Presentation).
  49. **Drobyski WR**, Gendelman M, Yassai M and Gorski J. Effective T cell reconstitution and retained graft versus leukemia reactivity after transplantation of thymidine kinase gene-modified donor T cells. 43rd Annual Meeting of the American Society of Hematology, Orlando, FL, Blood 98: 390a, 2001.
  50. **Drobyski WR** and Gendelman M. Regulated death of donor T cells mediated by bcl-xL is an integral component of the graft versus host reaction. 43rd Annual Meeting of the American Society of Hematology, Orlando, FL, Blood 98: 650a, 2001.
  51. **Drobyski WR**, Klein J, Flomenberg N, Pietryga D, Vesole D, Margolis D, Keever-Taylor C. Superior survival associated with transplantation of matched unrelated versus one antigen-mismatched unrelated or highly HLA-disparate haploidentical family donor marrow grafts for the treatment of hematological malignancies. 43rd Annual Meeting of the American Society of Hematology, Orlando, FL, Blood 98: 668a, 2001.
  52. Burt RK, **Drobyski WR**, Seregina T, Traynor A, Oyama Y, Keever-Taylor C, Rosen S, Kuzel T, Burns W, and Link C. Anti-tumor effectiveness of herpes simplex thymidine kinase gene transduced donor lymphocyte infusions for relapsed hematological malignancies following allogeneic hematopoietic stem cell transplantation. 43rd Annual Meeting of the American Society of Hematology, Orlando, FL, Blood 98: 698a, 2001.
  53. Margolis DA, Molter M, Skonecki J, Zeng H, Giesen B, **Drobyski WR**, Keever-Taylor CA. Rigorous T cell depletion achieved by single step CD34 selection using the Isolex 300i with version 2.5 software: Experience in healthy donors. 44th Annual Meeting of the American Society of Hematology, Philadelphia, PA, Blood
  54. **Drobyski WR**, Gendelman M, Vodanovic-Jankovic S, and Gorski J. Elimination of leukemia without lethal graft versus host disease. 44th Annual Meeting of the American Society of Hematology, Philadelphia, PA, 2002. (Poster Presentation).
  55. **Drobyski WR**, Hecht T, and Gendelman M. Effect of interleukin 7 on murine graft versus host disease. 44th Annual Meeting of the American Society of Hematology, Philadelphia, PA, 2002. (Poster Presentation).
  56. **Drobyski WR**, Gendelman M, Yassai M, Tivol E, Krueger A, and Gorski J. Selective elimination of

- alloreactive donor T cells attenuates graft versus host disease and enhances T cell reconstitution. 45th Annual Meeting of the American Society of Hematology Meeting, San Diego, CA, 2003 (Poster Presentation).
57. Thumma S, Hari P, Bredeson C, **Drobyski W**, Flomenberg N, Horowitz M, Johnson V, Keever-Taylor C, Phillips G, Reece D, Rizzo D, Wade J, Vesole D. Phase I/II trial of dose escalation of melphalan with amifostine cytoprotection supported by autologous hematopoietic stem cell transplant in multiple myeloma, 45th Annual Meeting of the American Society of Hematology Meeting, San Diego, CA, 2003
  58. Hari P, Thumma S, Bredeson C, **Drobyski W**, Horowitz M, Kovatovic K, Olson L, Johnson V, Keever-Taylor C, Rizzo D, Wade J, Vesole D. Paroxysmal atrial fibrillation as a complication of autologous stem cell transplant with higher doses of melphalan in multiple myeloma patients. 45th Annual Meeting of the American Society of Hematology Meeting, San Diego, CA, 2003
  59. Hari P, Logan B and **Drobyski WR**. Temporally discordant graft versus leukemia and graft versus host responses after donor lymphocyte infusion therapy for relapsed chronic myelogenous leukemia. American Society for Blood and Marrow Transplantation, Orlando, FL, 2004 (Poster Presentation).
  60. Hari P, Vodanovi-Jankovic S, Jacobs P, Komorowski R and **Drobyski WR**. NF- $\kappa$ B as a target for the prevention of graft versus host disease: Comparative efficacy of bortezomib and PS-1145. American Society of Hematology, Atlanta, GA 2005. (Poster Presentation).
  61. Chen X, Gorski J, Gendelman M, Yassai M, Krueger A, Tivol E, Logan B, Komorowski R, Vodanovic-Jankovic S, **Drobyski WR**. Homeostatic expansion and repertoire regeneration of donor T cells during graft versus host disease is constrained by the host environment. 48th Annual Meeting of the American Society of Hematology, Orlando, FL 2006. (Oral Presentation).
  62. Haribhai D, Grewal J, Ziegelbauer J, Edwards B, Chen X, Verbsky J, **Drobyski W**, Chatila TA, Williams CB, Grossman WJ. Role of natural T regulatory cells in preventing myeloproliferative disease. Keystone Symposium of Regulatory T Cells, Vancouver, British Columbia, 2007 (Poster Presentation).
  63. Chen X, van Snick J, Uyttenhopve C, Komorowski R, **Drobyski WR**. Inhibition of interleukin 17 significantly attenuates the severity of autoimmune-mediated pathological damage in chronic graft versus host disease. 49th Annual Meeting of the American Society of Hematology, Atlanta, GA 2007 (Oral Presentation).
  64. Das R, Komorowski R, Ghilardi N, Hessner M, **Drobyski WR**. Critical role for donor antigen presenting cell secretion of interleukin 23 in the pathophysiology of graft versus host disease of the colon. American Society for Blood and Marrow Transplantation, San Diego, CA 2008 (Oral Presentation).
  65. Das R, Komorowski R, Hessner MJ, **Drobyski WR**. Interleukin 23 secretion by donor antigen presenting cells is critical for organ-specific pathology in graft versus host disease. University of Wisconsin Symposium on Immunology, Madison, WI, 2008 (Poster Presentation).
  66. Das R, Chen X, Komorowski R, Hessner MJ, **Drobyski WR**. Interleukin 23 secretion by donor antigen presenting cells is critical for organ-specific pathology in graft versus host disease. 50th Annual Meeting of the American Society of Hematology, San Francisco, CA 2008 (Oral Presentation).
  67. Chen X, Das R, Komorowski R, Mihara M, **Drobyski WR**. Blockade of interleukin 6 signaling attenuates graft versus host disease by augmenting regulatory T cell reconstitution. 50th Annual Meeting of the American Society of Hematology, San Francisco, CA 2008 (Oral Presentation).
  68. Zhu F, Tsao A, Xu H, **Drobyski WR**, Keever-Taylor CA. Optimization of conditions for the transduction of therapeutic T cells using a lentivirus vector. 15th Annual Meeting of the International Society of Cellular Therapy, San Diego, CA 2009
  69. Das R, Komorowski R, Hessner M, Subramanian H, Cua D, Huettner C, **Drobyski WR**. Blockade of IL-23 signaling results in targeted protection of the colon and allows for separation of graft versus host and graft versus leukemia effects. 51st Annual Meeting of the American Society of Hematology, New Orleans, LA, 2009 (Oral Presentation).
  70. Das R, Subramanian H, Komorowski R, Hessner M, **Drobyski WR**. Blockade of Interleukin 23 signaling allows for separation of GVH and GVL effects in both acute and chronic models of leukemia. Medical College of Wisconsin Annual Research Day, Winner of Outstanding Poster Award for Post Graduate Student in Basic Research, September 2009.
  71. Coghil C, **Drobyski WR**, Komorowski R. Gastrointestinal pathology of autologous graft versus host disease following hematopoietic progenitor cell transplantation. United States and Canadian Academy of Pathology 99th Annual Meeting, Washington DC, March 2010.
  72. Hallett, WHD, **Drobyski WR**, Johnson BD. Blockade of the PD-1 pathway improves immunotherapy for

multiple myeloma.

73. Beres A, Komorowski R, **Drobyski WR**. Stability of Foxp3 expression is a critical factor in the ability of regulatory T cells to mitigate graft versus host disease. 52nd Annual Meeting of the American Society of Hematology, Orlando, FL, 2010 (Oral Presentation).